Kennislacunes

What is the effectivity and safety of second-line immunotherapy (atezolizumab, nivolumab en pembrolizumab)) with PD-1-, PD-L1- and CTLA4-inhibitors in patients with non–small-cell lung cancer stage IIIB/IV without sensitizing oncogene driver mutations compared to chemotherapy?

 

What is the effectivity and safety of second-line immunotherapy with PD-1-, PD-L1- and CTLA4-inhibitors in patients with non–small-cell lung cancer stage IIIB/IV and performance score 2, without sensitizing oncogene driver mutations compared to chemotherapy?

 

What is the effect on quality of life of second-line immunotherapy with PD-1-, PD-L1- and CTLA4-inhibitors in patients with non–small-cell lung cancer stage IIIB/IV without sensitizing oncogene driver mutations compared to chemotherapy?

 

What is the most optimal during of therapy for the second-line immunotherapy based treatment ?